Prophylactic Antimicrobials Overused in Urologic Surgery

This article originally appeared here.
Share this content:
Prophylactic Antimicrobials Overused in Urologic Surgery
Prophylactic Antimicrobials Overused in Urologic Surgery

FRIDAY, Jan. 23, 2015 (HealthDay News) -- Utilization patterns indicate that antimicrobial prophylaxis is overused for urological surgeries in the community practice setting, according to research published in the February issue of The Journal of Urology.

In an effort to assess patterns of use for antimicrobial prophylaxis in a large, community-based population, Matthew Mossanen, M.D., of the University of Washington in Seattle, and colleagues analyzed data for patients undergoing certain urological surgeries. Index urological surgeries included radical prostatectomy, partial or radical nephrectomy, radical cystectomy, ureteroscopy, shock wave lithotripsy, transurethral resection of the prostate, percutaneous nephrostolithotomy, transvaginal surgery, inflatable penile prosthesis, brachytherapy, transurethral resection of bladder tumor, and cystoscopy.

The researchers found that overall compliance with antimicrobial prophylaxis recommended in the 2008 American Urological Association (AUA) Best Practice Policy Statement was 53 percent, with rates ranging from 0.6 percent for radical cystectomy to 97 percent for shock wave lithotripsy. Utilization patterns showed use of antimicrobial agents in the appropriate class in 67 percent of cases (range, 34 to 80 percent) and for the recommended duration of therapy in 78 percent (range, 1.2 to 98 percent). The average duration of therapy for procedures in which antimicrobial prophylaxis is recommended ranged from 1.1 days after brachytherapy to 10.3 days after radical cystectomy. The overall rate of compliance with the AUA Best Practice Policy Statement increased from 46 percent in 2007 to 59 percent in 2012.

"In most cases, noncompliance was due to an inappropriately long duration of antimicrobial administration," the authors write.

One author disclosed financial interest in and/or other relationship with The Journal of Urology.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths